MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Levodopa(L-dopa)"

  • 2024 International Congress

    Continuous Dopaminergic Stimulation-based Levodopa Treatment in Early to Mid-stage Parkinson’s Disease Patients: A Systematic Review and Meta-analysis

    R. Tang, R. Sun, S. Zhang, L. Chen (Shanghai, China)

    Objective: To compare the clinical effectiveness between continuous dopaminergic stimulation (CDS)-based and intermittent levodopa (IL) treatment in patients with early to mid-stage Parkinson’s disease (PD).…
  • 2024 International Congress

    Dopa-responsive ataxia with compound heterozygous variants in MRE11

    A. Dugar, E. Levine, M. Barbosa, W. Tse (New York, USA)

    Objective: To evaluate the role for levodopa in patients with ataxia telangiectasia like disorder (ATLD) who have a compound heterozygous mutation in MRE11. Background: Early-onset…
  • 2024 International Congress

    Efficacy and Safety of Foslevodopa/Foscarbidopa in People With Parkinson’s Disease With and Without Care Partner Support

    M. Soileau, J. Bronstein, L. Harmer, M. Shah, R. Gupta, L. Verhagen Metman (Georgetown, USA)

    Objective: To assess the efficacy and safety of foslevodopa/foscarbidopa (LDp/CDp) in people with Parkinson’s (PwP) with and without care partner support. Background: The progression of…
  • 2024 International Congress

    An observational study of the efficacy, safety, and discontinuation rate of foslevodopa/foscarbidopa in 22 patients with advanced Parkinson’s disease

    D. Kamiyama, N. Nishikawa, C. Abe, H. Iwaki, G. Oyama, T. Hatano, N. Hattori (Bunkyo, Japan)

    Objective: The aim of this observational study for PD patients treated with foslevodopa/foscarbidopa(LDP/CDP) is to evaluate clinical characteristics, therapeutic efficacy and safety, and to determine…
  • 2024 International Congress

    Altered EEG Theta Activity Characterizes Parkinson’s disease with Levodopa-induced Dyskinesia

    M. Sciascia, A. Castelnovo, I. Bertaina, C. Desperati, C. Steadler, A. Kaelin, S. Galati (Lugano, Switzerland)

    Objective: We explored the relationship between the build-up and the downscaling process in patients with Parkinson’s disease by analyzing theta frequency spectral bands. Background: During…
  • 2024 International Congress

    Impact of IPX203 on Parkinson’s patients’ motor states upon awakening: analysis of patient diary data

    S. Isaacson, H. Fernandez, C. Kilbane, G. Banisadr, A. Pitman, S. Fisher, R. D'Souza (Boca Raton, USA)

    Objective: To evaluate “On” upon awakening in Parkinson’s disease patients taking IPX203 in the RISE-PD phase 3 clinical trial. Background: IPX203 is a novel extended-release,…
  • 2024 International Congress

    A Preliminary Report on the Clinical Profile of People with PD at an Outpatient Clinic in Malawi

    M. Gwedela, T. Phiri (Blantyre, Malawi)

    Objective: The objective of the study is to analyze the clinical and socio-demographic characteristics of people with Parkinson`s (PwP) attending the adult neurology outpatient clinic…
  • 2024 International Congress

    Genetic Variants and Levodopa Response in Parkinson’s Disease: Insights from MAO-B and DAT1 Polymorphisms

    S. Sarkar, A. Biswas, S. Ansari, S. Sengupta, S. Choudhury, R. Banerjee, S. Chatterjee, S. Dey, H. Kumar (Kolkata, India)

    Objective: This study aimed to find the association of genetic variations between Parkinson’s disease (PD) patients with and without levodopa-induced dyskinesia (LID). we intended to…
  • 2023 International Congress

    Machine Learning Model for Prediction of acute orthostatic hypotension after levodopa administration

    Z. Liu, SN. Lin, ZL. Chen, Y. Ling, T. Feng (Beijing, China)

    Objective: The aim of this study is to develop and validate a prediction model of AOHPL to facilitate physicians in identifying patients at higher probability…
  • 2023 International Congress

    Tremor characteristics differentially respond to levodopa and subthalamic nucleus deep brain stimulation in Parkinson’s disease

    T. Wirth, F. Ferreira, N. Vijiaratnam, C. Girges, A. Pakzad, A. Roquemaurel, O. Sinani, J. Hyam, M. Hariz, L. Zrinzo, H. Akram, P. Limousin, T. Foltynie (Strasbourg, France)

    Objective: To identify factors predictive of responsiveness of tremor to levodopa and STN-DBS. Background: Tremor in Parkinson’s disease (PD) is phenotypically variable and has an…
  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 62
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley